Biomerica, Inc. (BMRA)


+0.27 (+7.20%)
Symbol BMRA
Price $3.9663
Beta -0.531
Volume Avg. 0.09M
Market Cap 53.258M
Shares () -
52 Week Range 2.56-5.25
1y Target Est -
DCF Unlevered BMRA DCF ->
DCF Levered BMRA LDCF ->
ROE -57.33% Strong Sell
ROA -45.79% Strong Sell
Operating Margin -
Debt / Equity 32.79% Neutral
P/E -14.17 Strong Sell
P/B 6.24 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest BMRA news

Mr. Zackary Irani
Medical Devices
NASDAQ Capital Market

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; Helicobacter pylori test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.